Skip navigation
Please use this identifier to cite or link to this item: https://repositorio.unb.br/handle/10482/36701
Files in This Item:
File SizeFormat 
ARTIGO_BrazilianRecommendationsSafety.pdf943,49 kBAdobe PDFView/Open
Title: Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases
Authors: Pileggi, Gecilmara Salviato
Mota, Licia Maria Henrique da
Kakehasi, Adriana Maria
Souza, Alexandre Wagner de
Rocha, Aline
Melo, Ana Karla Guedes de
Fonte, Caroline Araujo M. da
Bortoletto, Cecilia
Brenol, Claiton Viegas
Marques, Claudia Diniz Lopes
Zaltman, Cyrla
Borba, Eduardo Ferreira
Reis, Enio Ribeiro
Freire, Eutilia Andrade Medeiros
Klumb, Evandro Mendes
Christopoulos, Georges Basile
Laurindo, Ieda Maria M.
Ballalai, Isabella
Costa, Izaias Pereira da
Michelin, Lessandra
Valadares, Lilian David de Azevêdo
Chebli, Liliana Andrade
Lacerda, Marcus
Toscano, Maria Amazile Ferreira
Yazbek, Michel Alexandre
Vieira, Rejane Maria R. de Abreu
Magalhães, Renata
Kfouri, Renato
Richtmann, Rosana
Merenlender, Selma da Costa Silva
Valim, Valeria
Assis, Marcos Renato de
Kowalski, Sergio Candido
Trevisani, Virginia Fernandes Moça
metadata.dc.identifier.orcid: http://orcid.org/0000-0003-0054-7754
Issue Date: 2019
Publisher: Sociedade Brasileira de Reumatologia
Citation: PILEGGI, Gecilmara Salviato et al. Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases. Advances in Rheumatology, v. 59,17, 2019. DOI: https://doi.org/10.1186/s42358-019-0056-x. Disponível em: http://scielo.br/scielo.php?script=sci_arttext&pid=S2523-31062019000100302. Acesso em: 23 jan. 2020.
Abstract: Background: In Brazil, we are facing an alarming epidemic scenario of Yellow fever (YF), which is reaching the most populous areas of the country in unvaccinated people. Vaccination is the only effective tool to prevent YF. In special situations, such as patients with chronic immune-mediated inflammatory diseases (CIMID), undergoing immunosuppressive therapy, as a higher risk of severe adverse events may occur, assessment of the risk-benefit ratio of the yellow fever vaccine (YFV) should be performed on an individual level. Main body of the abstract: Faced with the scarcity of specific orientation on YFV for this special group of patients, the Brazilian Rheumatology Society (BRS) endorsed a project aiming the development of individualized YFV recommendations for patients with CIMID, guided by questions addressed by both medical professionals and patients, followed an internationally validated methodology (GIN-McMaster Guideline Development). Firstly, a systematic review was carried out and an expert panel formed to take part of the decision process, comprising BRS clinical practitioners, as well as individuals from the Brazilian Dermatology Society (BDS), Brazilian Inflammatory Bowel Diseases Study Group (GEDIIB), and specialists on infectious diseases and vaccination (from Tropical Medicine, Infectious Diseases and Immunizations National Societies); in addition, two representatives of patient groups were included as members of the panel. When the quality of the evidence was low or there was a lack of evidence to determine the recommendations, the decisions were based on the expert opinion panel and a Delphi approach was performed. A recommendation was accepted upon achieving ≥80% agreement among the panel, including the patient representatives. As a result, eight recommendations were developed regarding the safety of YFV in patients with CIMID, considering the immunosuppression degree conferred by the treatment used. It was not possible to establish recommendations on the effectiveness of YFV in these patients as there is no consistent evidence to support these recommendations. Conclusion: This paper approaches a real need, assessed by clinicians and patient care groups, to address specific questions on the management of YFV in patients with CIMID living or traveling to YF endemic areas, involving specialists from many areas together with patients, and might have global applicability, contributing to and supporting vaccination practices. We recommended a shared decision-making approach on taking or not the YFV.
Licença:: © The Author(s). 2019 Open Access - This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
DOI: https://doi.org/10.1186/s42358-019-0056-x
Appears in Collections:FMD - Artigos publicados em periódicos

Show full item record Recommend this item " class="statisticsLink btn btn-primary" href="/handle/10482/36701/statistics">



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.